Agilent Technologies (NYSE:A) Shares Acquired Rep. Robert Bresnahan, Jr.

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of Agilent Technologies, Inc. NYSE: A. In a filing disclosed on May 31st, the Representative disclosed that they had bought between $1,001 and $15,000 in Agilent Technologies stock on May 15th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Zimmer Biomet NYSE: ZBH on 5/15/2025.
• Sold $15,001 - $50,000 in shares of Elevance Health NYSE: ELV on 5/15/2025.
• Sold $15,001 - $50,000 in shares of PepsiCo NASDAQ: PEP on 5/15/2025.
• Sold $1,001 - $15,000 in shares of WEC Energy Group NYSE: WEC on 5/15/2025.
• Purchased $15,001 - $50,000 in shares of Advanced Micro Devices NASDAQ: AMD on 5/15/2025.
• Purchased $1,001 - $15,000 in shares of Hershey NYSE: HSY on 5/15/2025.
• Purchased $1,001 - $15,000 in shares of Kraft Heinz NASDAQ: KHC on 5/15/2025.
• Sold $1,001 - $15,000 in shares of Exxon Mobil NYSE: XOM on 5/15/2025.
• Sold $1,001 - $15,000 in shares of Danaher NYSE: DHR on 5/15/2025.
• Sold $1,001 - $15,000 in shares of International Flavors & Fragrances NYSE: IFF on 5/15/2025.

Agilent Technologies Stock Up 2.1%

A stock traded up $2.35 during mid-day trading on Wednesday, hitting $115.11. 2,692,784 shares of the company were exchanged, compared to its average volume of 1,925,403. The company has a market capitalization of $32.82 billion, a PE ratio of 28.42, a price-to-earnings-growth ratio of 3.37 and a beta of 1.23. The company has a current ratio of 2.09, a quick ratio of 1.60 and a debt-to-equity ratio of 0.55. Agilent Technologies, Inc. has a twelve month low of $96.43 and a twelve month high of $153.84. The firm has a fifty day simple moving average of $108.14 and a 200 day simple moving average of $126.18.

Agilent Technologies (NYSE:A - Get Free Report) last announced its quarterly earnings data on Wednesday, May 28th. The medical research company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.05. The company had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.63 billion. Agilent Technologies had a net margin of 17.59% and a return on equity of 25.92%. The firm's revenue for the quarter was up 6.0% compared to the same quarter last year. During the same period last year, the business earned $1.22 EPS. On average, research analysts forecast that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 23rd. Shareholders of record on Tuesday, July 1st will be issued a dividend of $0.248 per share. This represents a $0.99 annualized dividend and a yield of 0.86%. The ex-dividend date is Tuesday, July 1st. Agilent Technologies's dividend payout ratio is currently 24.44%.

Insider Buying and Selling

In other Agilent Technologies news, Director Daniel K. Podolsky sold 1,819 shares of Agilent Technologies stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $116.46, for a total value of $211,840.74. Following the completion of the sale, the director now directly owns 35,737 shares in the company, valued at $4,161,931.02. The trade was a 4.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Rodney Gonsalves sold 1,908 shares of Agilent Technologies stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $121.98, for a total transaction of $232,737.84. Following the completion of the sale, the vice president now owns 21,786 shares of the company's stock, valued at $2,657,456.28. This trade represents a 8.05% decrease in their ownership of the stock. The disclosure for this sale can be found here.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Jefferies Financial Group reduced their price target on shares of Agilent Technologies from $135.00 to $116.00 and set a "hold" rating on the stock in a research report on Monday, April 21st. Robert W. Baird cut their price objective on shares of Agilent Technologies from $159.00 to $140.00 and set an "outperform" rating on the stock in a research report on Thursday, May 22nd. TD Cowen lifted their price objective on shares of Agilent Technologies to $150.00 and gave the company a "buy" rating in a research report on Thursday, May 29th. Wells Fargo & Company cut their price objective on shares of Agilent Technologies from $155.00 to $135.00 and set an "overweight" rating on the stock in a research report on Thursday, April 17th. Finally, Barclays cut their price objective on shares of Agilent Technologies from $138.00 to $115.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th. Seven research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $140.15.

Hedge Funds Weigh In On Agilent Technologies

Large investors have recently bought and sold shares of the stock. Modern Wealth Management LLC boosted its holdings in shares of Agilent Technologies by 36.2% during the first quarter. Modern Wealth Management LLC now owns 2,732 shares of the medical research company's stock worth $320,000 after purchasing an additional 726 shares during the period. Ellsworth Advisors LLC acquired a new stake in shares of Agilent Technologies during the first quarter worth approximately $800,000. Foresight Group Ltd Liability Partnership acquired a new stake in shares of Agilent Technologies during the first quarter worth approximately $27,434,000. Advisors Capital Management LLC boosted its holdings in shares of Agilent Technologies by 2.9% during the first quarter. Advisors Capital Management LLC now owns 62,270 shares of the medical research company's stock worth $7,284,000 after purchasing an additional 1,784 shares during the period. Finally, Acadian Asset Management LLC boosted its holdings in shares of Agilent Technologies by 16.5% during the first quarter. Acadian Asset Management LLC now owns 5,352 shares of the medical research company's stock worth $625,000 after purchasing an additional 758 shares during the period.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.